Phase II trial of fludarabine phosphate in multiple myeloma using a loading dose and continuous infusion schedule
Immunoglobulin Light Chains
Immunoglobulin Variable Region
Leukemia, Lymphocytic, Chronic, B-Cell
A phase II trial of fludarabine phosphate using a bolus and continuous infusion regimen in previously treated multiple myeloma was performed. No responses were observed in eleven patients. There was no significant non-hematologic toxicity noted. Fludarabine phosphate is inactive in multiple myeloma using this schedule.